IMF-ONS 2022

Learning Objectives:

At the conclusion of the educational presentation, the participant will be able to:


  • Discuss new and emerging therapies, including CELMoDs®, CAR-T cell therapy, and T-cell engagers, such as bispecific antibodies, for patients with multiple myeloma, including AE management and patient education
  • Discuss the importance of sequencing therapy, including the use of multidrug regimens and bridging therapy
  • Use strategies to support the attainment of deep responses by myeloma patients, such as new therapies, multidrug regimens, ASCT, maintenance, adherence, shared decision-making, MRD and other testing
  • Identify disparities faced by patients with multiple myeloma and strategies to overcome these (health equity)
  • Support patient and care partner’s (caregiver’s) input in treatment decisions through shared decision-making throughout the patient journey